<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Clinical characteristics of psychiatric patients stratified by achieving SVR-12</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>SVR-12 
     <italic>(N = 127)</italic>
    </th>
    <th>No SVR-12 
     <italic>(N = 17)</italic>
    </th>
    <th>
     <bold>
      <italic>p-value</italic>
     </bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>Sex, males.</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>58 (45.7%)</td>
    <td>13 (76.5%)</td>
    <td>
     <bold>0.020</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Age, years, mean (SD)</bold>
    </td>
    <td>61.8 ± 13.3</td>
    <td>51.6 ± 11.7</td>
    <td>
     <bold>0.038</bold>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <bold>Risk Factors</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>IDU</italic>
    </td>
    <td>28 (22.0%)</td>
    <td>9 (52.9%)</td>
    <td>
     <bold>0.014</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>Heterosexual</italic>
    </td>
    <td>10 (7.9%)</td>
    <td>0</td>
    <td>0.607</td>
   </tr>
   <tr>
    <td>
     <italic>MSM</italic>
    </td>
    <td>1 (0.8%)</td>
    <td>0</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td> Nosocomial</td>
    <td>36 (28.3%)</td>
    <td>2 (11.8%)</td>
    <td>0.239</td>
   </tr>
   <tr>
    <td>
     <italic>Unknown</italic>
    </td>
    <td>52 (41.0%)</td>
    <td>6 (35.3%)</td>
    <td>0.794</td>
   </tr>
   <tr>
    <td colspan="4">
     <bold>HCV Genotypes</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td>
     <italic>1a</italic>
    </td>
    <td>27 (21.3%)</td>
    <td>5 (29.4%)</td>
    <td>0.534</td>
   </tr>
   <tr>
    <td>
     <italic>1b</italic>
    </td>
    <td>45 (35.4%)</td>
    <td>6 (35.3%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <italic>2</italic>
    </td>
    <td>35 (27.6%)</td>
    <td>2 (11.8%)</td>
    <td>0.238</td>
   </tr>
   <tr>
    <td>
     <italic>3</italic>
    </td>
    <td>15 (11.8%)</td>
    <td>3 (17.6%)</td>
    <td>0.448</td>
   </tr>
   <tr>
    <td>
     <italic>4</italic>
    </td>
    <td>5 (3.9%)</td>
    <td>1 (5.9%)</td>
    <td>0.536</td>
   </tr>
   <tr>
    <td>
     <bold>Log 10 HCV-RNA, IU/mL, median (range)</bold>
    </td>
    <td>6.00 (5.5–6.5)</td>
    <td>6.1 (5.5–6.7)</td>
    <td>0.841</td>
   </tr>
   <tr>
    <td>
     <bold>Liver stiffness, Kpa, mean (SD)</bold>
    </td>
    <td>11.1 ± 10.4</td>
    <td>8.9 ± 3.4</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>Previous failure,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>24 (18.9%)</td>
    <td>8 (47.0%)</td>
    <td>
     <bold>0.024</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>INF-based tx</bold>
    </td>
    <td>23</td>
    <td>8</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>DAAs-based tx</bold>
    </td>
    <td>1</td>
    <td>0</td>
    <td/>
   </tr>
   <tr>
    <td>
     <bold>FIB-4 score median (range)</bold>
    </td>
    <td>2.0 (1.4–3.3)</td>
    <td>1.5 (1.3–2.1)</td>
    <td>0.226</td>
   </tr>
   <tr>
    <td>
     <bold>APRI score median (range)</bold>
    </td>
    <td>0.6 (0.4–1.2)</td>
    <td>0.6 (0.5–1.2)</td>
    <td>0.936</td>
   </tr>
   <tr>
    <td>
     <bold>MELD score median (range)</bold>
    </td>
    <td>7.0 (6.0–8.0)</td>
    <td>7.0 (6.0–7.0)</td>
    <td>0.794</td>
   </tr>
   <tr>
    <td>
     <bold>Cirrhosis,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>40 (31.5%)</td>
    <td>6 (35.3%)</td>
    <td>0.785</td>
   </tr>
   <tr>
    <td>
     <bold>Oesophageal varices or portal hypertension,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>13 (10.2%)</td>
    <td>2 (11.8%)</td>
    <td>0.691</td>
   </tr>
   <tr>
    <td colspan="4">
     <bold>Type of HCV therapy</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
   </tr>
   <tr>
    <td> SOF + RBV</td>
    <td>7 (5.5%)</td>
    <td>0</td>
    <td>0.594</td>
   </tr>
   <tr>
    <td> SOF + SMV ± RBV</td>
    <td>5 (3.9%)</td>
    <td>0</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td> SOF + LDV ± RBV</td>
    <td>18 (14.2%)</td>
    <td>3 (17.6%)</td>
    <td>0.715</td>
   </tr>
   <tr>
    <td> SOF + DCV ± RBV</td>
    <td>11 (8.7%)</td>
    <td>2 (11.8%)</td>
    <td>0.652</td>
   </tr>
   <tr>
    <td> OMB + PTV/r + DAS ± RBV</td>
    <td>13 (10.2%)</td>
    <td>2 (11.8%)</td>
    <td>0.691</td>
   </tr>
   <tr>
    <td> OMB + PTV/r + RBV</td>
    <td>1 (0.8%)</td>
    <td>1 (5.9%)</td>
    <td>0.222</td>
   </tr>
   <tr>
    <td> SOF + VEL ± RBV</td>
    <td>30 (23.6%)</td>
    <td>7 (41.2%)</td>
    <td>0.141</td>
   </tr>
   <tr>
    <td> GLE + PIB</td>
    <td>24 (18.9%)</td>
    <td>0</td>
    <td>0.076</td>
   </tr>
   <tr>
    <td> GRZ + EBR ± RBV</td>
    <td>18 (14.2%)</td>
    <td>2 (11.8%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <bold>Addition of RBV</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>27 (21.2%)</td>
    <td>6 (35.3%)</td>
    <td>0.222</td>
   </tr>
   <tr>
    <td>
     <bold>ALT, UI/L, median (range)</bold>
    </td>
    <td>50 (28.5–77.5)</td>
    <td>70 (47–125)</td>
    <td>
     <bold>0.031</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Total bilirubin, mg/dL, median (range)</bold>
    </td>
    <td>0.62 (0.44–0.83)</td>
    <td>0.60 (0.40–0.80)</td>
    <td>0.561</td>
   </tr>
   <tr>
    <td>
     <bold>Serum creatinine, mg/dL, median (range)</bold>
    </td>
    <td>0.79 (0.61–0.95)</td>
    <td>0.78 (0.63–0.80)</td>
    <td>0.928</td>
   </tr>
   <tr>
    <td>
     <bold>Platelets (×10^9/L), median (range)</bold>
    </td>
    <td>182 (139–219)</td>
    <td>185 (157–210)</td>
    <td>0.920</td>
   </tr>
   <tr>
    <td>
     <bold>Patients with at least 1 other comorbidity, n (%)</bold>
    </td>
    <td>94 (74%)</td>
    <td>7 (41.2%)</td>
    <td>
     <bold>0.009</bold>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Diabetes,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>18 (14.2%)</td>
    <td>2 (11.8%)</td>
    <td>1.000</td>
   </tr>
   <tr>
    <td>
     <bold>Hypertension,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>57 (44.9%)</td>
    <td>4 (23.5%)</td>
    <td>0.119</td>
   </tr>
   <tr>
    <td>
     <bold>HIV infected,</bold>
     <bold>
      <italic>n</italic>
     </bold>
     <bold>(%)</bold>
    </td>
    <td>17 (13.4%)</td>
    <td>2 (11.8%)</td>
    <td>1.000</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Legend</italic>: 
   <italic>IDU</italic> Injecting drug user, 
   <italic>MSM</italic> Man who have sex with man, 
   <italic>INF</italic> Interferon, 
   <italic>DAA</italic> Direct antiviral agent, 
   <italic>SOF</italic> Sofosbuvir, 
   <italic>RBV</italic> Ribavirin, 
   <italic>SMV</italic> Simeprevir, 
   <italic>LDV</italic> Ledipasvir, 
   <italic>DCV</italic> Daclatasvir, 
   <italic>OMB</italic> Ombitasvir, 
   <italic>PTV/r</italic> Paripatrevir/ritonavir, 
   <italic>DSV</italic> Dasabuvir, 
   <italic>VEL</italic> Velpatasvir, 
   <italic>GLE</italic> Glecaprevir, 
   <italic>PIB</italic> Pibrentasvir, 
   <italic>GRZ</italic> Grazoprevir, 
   <italic>EBR</italic> Elbasvir, 
   <italic>ALT</italic> Alanine aminotransferase, 
   <italic>ART</italic> Antiretroviral therapy
  </p>
 </table-wrap-foot>
</table-wrap>
